Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 1, 2011, Pages 27-33

  Kiewe, Philipp ^a   Neumann, Martin ^a   Wagner, Thomas ^b   Seyfert, Sepp ^a   Albrecht, Heike ^b   Thiel, Eckhard ^a   Korfel, Agnieszka ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

4 OH ifosfamide; Blood CSF barrier; Cerebrospinal fluid; CNS malignancies; CSF penetration; Ifosfamide

Indexed keywords

4 HYDROXYIFOSFAMIDE; DEXAMETHASONE; DRUG METABOLITE; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD CEREBROSPINAL FLUID BARRIER; BREAST CANCER; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG PENETRATION; FEMALE; HUMAN; LYMPHOMA; MALE; NEUROTOXICITY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PERMEABILITY;

EID: 78651095772     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1274-4     Document Type: Article

References (21)

1. F Rodeghiero F Elice 2003 Ifosfamide in hematological malignancies of adults Oncology 65 Suppl 2 85 93 1:CAS:528:DC%2BD3sXosF2msb8%3D 10.1159/000073367 14586156 (Pubitemid 37346739)
2. V Sneller J Armitage 2003 Current role and future perspectives for ifosfamide in the treatment of malignant non-Hodgkin's lymphoma-results from an expert meeting Ann Oncol 14 Suppl 1 i1 i3 10.1093/annonc/mdg701 12736223
3. M Tascilar WJ Loos C Seynaeve J Verweij S Sleijfer 2007 The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas Oncologist 12 1351 1360 1:CAS:528:DC%2BD1cXivVShtQ%3D%3D 10.1634/theoncologist. 12-11-1351 18055856 (Pubitemid 350232609)
4. SK Brüggemann K Radike K Braasch, et al. 2006 Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite Cancer Chemother Pharmacol 57 349 356 10.1007/s00280-005-0061-0 16133533
5. J Zhang Q Tian S Yung Chan, et al. 2005 Metabolism and transport of oxazaphosphorines and the clinical implications Drug Metab Rev 37 611 703 1:CAS:528:DC%2BD28XmslWg 10.1080/03602530500364023 16393888 (Pubitemid 43071142)
6. F Lokiec 2006 Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention Ann Oncol 17 Suppl 4 iv33 iv36 10.1093/annonc/ mdj997 16702183 (Pubitemid 43778974)
7. BS Andersson M Mroue RA Britten D Farquhar D Murray 1995 Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line Acta Oncol 34 247 251 1:STN:280:DyaK2M3jsVensQ%3D%3D 10.3109/02841869509093963 7718264
8. H Reiber 1994 Flow rate of cerebrospinal fluid (CSF)-a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases J Neurol Sci 122 189 203 1:STN:280:DyaK2c3ptlSgtg%3D%3D 10.1016/0022-510X(94) 90298-4 8021703 (Pubitemid 24097269)
9. S Seyfert S Quill A Faulstich 2009 Variation of barrier permeability for albumin and immunoglobulin G influx into CSF Clin Chem Lab Med 47 955 958 1:CAS:528:DC%2BD1MXhtFahtLrL 10.1515/CCLM.2009.211 19548846
10. V Kurowski T Wagner 1993 Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy Cancer Chemother Pharmacol 33 36 42 1:CAS:528:DyaK2cXlvFCrsbw%3D 10.1007/BF00686020 8269587 (Pubitemid 23336498)
11. A Brinker J Kisro C Letsch SK Brüggemann T Wagner 2002 New insights into the clinical pharmacokinetics of trofosfamide Int J Clin Pharmacol Ther 40 376 381 1:CAS:528:DC%2BD38XmsVamsLc%3D 12467306
12. GP Kaijser PG Ter Riet J de Kraker, et al. 1997 Determination of 4-hydroxyifosfamide in biological matrices by high-performance liquid chromatography J Pharm Biomed Anal 15 773 781 1:CAS:528:DyaK2sXjtFCgurY%3D 10.1016/S0731-7085(96)01893-6 9172103 (Pubitemid 27171131)
13. PJ Creaven LM Allen DA Alford MH Cohen 1974 Clinical pharmacology of isophosphamide Clin Pharmacol Ther 16 77 86 1:STN:280:DyaE2c3nslKjsw%3D%3D 4602057
14. SM Yule L Price AD Pearson AV Boddy 1997 Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children Clin Cancer Res 3 1985 1992 1:CAS:528:DyaK2sXns1Ogs7k%3D 9815588
15. GP Kaijser J De Kraker A Bult WJ Underberg JH Beijnen 1998 Pharmacokinetics of ifosfamide and some metabolites in children Anticancer Res 18 1941 1949 1:CAS:528:DyaK1cXltF2lu7Y%3D 9677448
16. J Ninane R Baurain J de Kraker A Ferster A Trouet G Cornu 1989 Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children Cancer Chemother Pharmacol 24 Suppl 1 S2 S6 2503256
17. CA Arndt FM Balis CL McCully OM Colvin DG Poplack 1988 Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys Cancer Res 48 2113 2115 1:CAS:528:DyaL1cXhvFOktbc%3D 3349482
18. CA Arndt OM Colvin FM Balis CM Lester G Johnson DG Poplack 1987 Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys Cancer Res 47 5932 5934 1:CAS:528:DyaL1cXhsF2mtQ%3D%3D 3664493
19. SK Brüggemann J Kisro T Wagner 1997 Ifosfamide cytotoxicity on human tumor, renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide Cancer Res 57 2676 2680 9205076
20. ET Hedley-Whyte DW Hsu 1986 Effect of dexamethasone on blood-brain barrier in the normal mouse Ann Neurol 19 373 377 1:CAS:528:DyaL28XktlGrs7c%3D 10.1002/ana.410190411 3707089
21. VS Narang C Fraga N Kumar, et al. 2008 Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier Am J Physiol Cell Physiol 295 C440 C450 1:CAS:528:DC%2BD1cXhtVaktr%2FK 10.1152/ajpcell.00491.2007 18524938 (Pubitemid 352755780)